Category: Conference Coverage

Roflumilast Topical Foam, 0.3% (Zoryve, Arcutis) in Seb Derm: Reviewing Data on Patients With Diverse Skin Types

A subgroup analysis of the Phase 3 STRATUM trial of roflumilast topical foam, 0.3% in seborrheic dermatitis showed consistent efficacy.